Key Highlights

  • Capricor (NASDAQ:CAPR) closed up 26.49% on November 11, 2026, after closing about 10% lower the day before on its third quarter update.
  • The FDA's target action date for deramiocel, a cell therapy for Duchenne muscular dystrophy, is November 22, 2026.
  • An FDA advisory committee voted 9 to 3 in July against evidence that the therapy is effective for cardiomyopathy in the disease, a non-binding vote on a narrower indication.
  • The company reported a third quarter net loss of USD 42.7 million and about USD 199 million of cash, which it said funds operations for at least twelve months.

The Regulatory Setup

Capricor is seeking approval of deramiocel, an allogeneic cell therapy, for Duchenne muscular dystrophy. The FDA originally had an August 22 action date but extended it to November 22 after the company submitted an amendment containing 24-month open-label extension data and a refined proposed indication focused on upper limb function. The agency treated the amendment as a major one. In July, the agency's advisory committee for cellular, tissue and gene therapies voted 9 to 3 that the evidence did not support effectiveness for cardiomyopathy in the disease. That vote is not binding and addressed a narrower question than the broader application, and the committee did not vote on overall benefit and risk. Management said discussion of the upper limb data was directionally supportive. The stock had fallen sharply after the advisory meeting and is down about 69% for the year.

What the Latest Data and Call Said

On November 9, the company reported data from its HOPE-3 trial of 106 patients that met its primary upper limb endpoint at 12 months, and the shares rose 9.44%. Left ventricular ejection fraction favoured deramiocel by 1.8 points but missed statistical significance, with a p-value of 0.09. On its November 10 earnings call, the chief executive said the application is in its final review stages and that the case does not rest solely on unmet medical need. The Manufacturing Facility in San Diego supports an initial launch Volume for about 250 patients a year, with an expansion planned to support 2,000 to 2,500 patients, targeted for validation in the first half of 2027. Shares of Capricor (NASDAQ:CAPR) fell about 10% in the regular session on November 10 but rose about 5% after hours, and then jumped 26.49% on November 11 as traders positioned ahead of the decision.

A Binary Event With Real Risks

The outcome on or before November 22 will determine the stock's direction. Approval would give the company its first commercial product in a disease with few treatment Options and could trigger a re-rating. A complete response letter, which the advisory vote makes a real possibility, would likely send the shares sharply lower. Quarterly operating expenses of USD 44.7 million exceeded USD 26.3 million a year earlier because of pre-commercial and manufacturing scale-up, and the company cut its workforce by about 10% in the quarter. It also faces an ongoing arbitration with a commercial partner, which management said it does not expect to delay patient access if approved. Retail interest is very high, so Volatility may be extreme. Investors should treat a move of this size ahead of a regulatory deadline as speculation on a single event, not as a change in fundamentals.

Where Things Stand

Capricor (NASDAQ:CAPR) rose 26.49% on November 11, 2026 ahead of the FDA's November 22 decision on deramiocel, after a negative advisory vote in July and mixed trial data. Approval could transform the company, while a rejection could erase the gain. Cash of about USD 199 million funds at least twelve months of operations.